Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
CA 2457903 C · Owner: University Of Victoria Innovation And Development Corporation · Inventors: Buckley, James Thomas; Denmeade, Samuel R.; Isaacs, John T.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed herein are modified proaerolysin (PA) peptide. In some examples the , proteins include a prostate-specific protease cleavage site and can further include a prostate-tissue-specific binding domain which functionally replaces the native PA binding domain. In other examples The proteins include a furin , cleavage site and a prostate tissue-specific binding domain which functionally replaces the native PA binding domain. Methods of using such peptides to treat prostate cancer are also disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 23, 2002 and granted April 17, 2018. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 23, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 23, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.